We want to introduce you to Dr Andrew Kueh, member of Phenomics Australia’s Scientific Director’s team and Head of the Melbourne Advanced Genome Editing Centre (MAGEC) at the Olivia Newton-John Research Institute (ONJRI).
Meet Andrew:
Andrew completed his PhD at WEHI in 2012, gaining expertise in developmental epigenetics. With this background, he was recruited by WEHI in 2014 to establish the Melbourne Advance Gene Editing Centre (MAGEC). He led the transition of gene editing technologies within WEHI from traditional ES cell-based gene targeting approaches to the introduction of cutting-edge CRISPR/Cas9 gene targeting platforms. By combining his expertise in embryonic development, genomics and molecular biology, he has propelled WEHI to the forefront of CRISPR/Cas9 gene targeting and has generated more than 400 unique gene-modified mice using CRISPR/Cas9.
“ Phenomics Australia has enabled the development of cutting-edge research tools within our service platform, allowing us to provide Australian researchers with gene-modified mouse models for academic research and for use as pre-clinical models of human disease. Together with other Phenomics Australia nodes, we aim to deliver comprehensive and critical research infrastructure to advance Australian biomedical research.“ Dr Kueh said.
Phenomics Australia provides a national centre of expertise and service provision to deploy CRISPR for increased speed, efficiency, and decreased cost for the production of animal strains carrying targeted mutations while maintaining the expertise for traditional transgenic technologies. To meet the high demand for this platform, Phenomics Australia offers genome editing services through five nodes across Australia, operating at Monash, ANU, ONJCRI, SAHMRI and PeterMac.
With an established track record and reputation for excellence, our Genome Engineering team uses techniques such as CRISPR-mediated mutagenesis, classical gene targeting, and transgenesis to create optimal tools for your research delivering a comprehensive service in genome modification. Phenomics Australia continues to develop and expand mutagenesis capabilities through in-house research and development, information exchange between service nodes, other CRISPR practitioners, and thorough literature review, thereby establishing a national community of practice for genome engineering technologies and applications. With our collective experience and expertise in a wide variety of projects, Phenomics Australia can assist in the production of genetically modified animal models. By providing a leading capability to make genetic associations with disease, Phenomics Australia makes the cost of investigating pathways associated with disease affordable.
